By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Chronix Biomedical said today that it has reeled in $1.8 million in Series E financing from existing and new investors that it is using to develop its serum-based disease tests.

The company's testing technology uses disease-specific biomarkers based on DNA fragments from damaged and dying cells that circulate in the bloodstream and are applicable to a range of cancers and other diseases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.